medigraphic.com
Patología Revista Latinoamericana

2010, Número 3

<< Anterior Siguiente >>

Patol Rev Latinoam 2010; 48 (3)


Aplicaciones prácticas de la inmunohistoquímica en la patología de la glándula mamaria

Vilches CN, Barboza QO, Garza GR, Ancer RJ, Flores GJP

Idioma: Español
Referencias bibliográficas: 53
Paginas: 194-203
Archivo PDF: 586.63 Kb.


RESUMEN

Los procesos patológicos que afectan la glándula mamaria son muy variados, lo que convierte su diagnóstico en un reto para el patólogo. El advenimiento de la inmunohistoquímica ha facilitado en gran medida la realización de diagnósticos certeros. El presente artículo revisa los marcadores inmunohistoquímicos que se utilizan con mayor frecuencia en el diagnóstico de las enfermedades de la glándula mamaria desde una perspectiva diagnóstica, pronóstica y predictiva. Entre las principales aplicaciones de esta técnica se encuentran: lesiones proliferativas epiteliales, lesiones papilares, carcinoma in situ ductal vs lobulillar, lesiones esclerosantes y carcinoma in situ vs carcinoma invasor.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Dabbs DJ, Taylor CR, Shi SR, Barr N. Techniques of immunohistochemistry: Principles, pitfalls and standardization. 3rd ed. Philadelphia, PA: Schmitt W, 2002;p:13-18.

  2. Bhargava R, Dabbs D. Use of immunohistochemistry in diagnosis of breast epithelial lesions. Adv Anat Pathol 2007;14:93- 107.

  3. Yeh T, Mies C. Application of immunohistochemistry to breast lesions. Arch Pathol Lab Med 2008;132:349-358.

  4. Lerwill M. Current practical applications of diagnostic immunohistochemistry in breast pathology. Am J Surg Pathol 2004;28:1076-1091.

  5. Hill CB, Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions: from intraductal papillomas to invasive papillary carcinomas. Am J Surg Pathol 2005;123:36-44.

  6. Sheridan T, Ioffe OB. Papillary lesions of the breast. Pathology Case Reviews 2009;14:147-156.

  7. Mulligan AM, O’Malley FP. Papillary lesions of breast: a review. Adv Anat Pathol 2007;14:108-119.

  8. Douglas-Jones A, Shah V, Morgan J, Dallimore N, Rashid N. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63. Histopathology 2005;47:202-208.

  9. Shah VI, Flowers CI, Douglas-Jones AG, Dallimore NS, Rashid N. Immunohistochemistry increases the accuracy of diagnosisof benign papillary lesions in breast core needle specimens. Histopathology 2006;48:683-691.

  10. Tse G, Tan P-H, Lui PC, Gilks CB, et al. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and CK14 in the differential diagnosis of papillary lesions of breast. J Clin Pathol 2007;60:315-320.

  11. Lehr HA, Folpe A, Yaziji H, Kommoss F, Gown AM. Cytoqueratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 2000;114:190-196.

  12. Jacobs TW, Pliss N, Kouria G, Schnitt SJ. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am J Surg Pathol 2001;25:229- 236.

  13. Conteras A, Saltar H. Lobular neoplasia of the breast. Arch Pathol Lab Med 2009;133:1116-1120.

  14. Da Silva L, Parry S, Reid L. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008;32:773-783.

  15. Willebrand D, Bosman FT, de Goeij AF. Patterns of basement membrane deposition in benign and malignant breast tumors. Histopathology 1986;10:1231-1241.

  16. Gimaraes N, Schenka AA, de Souza L, de Almeida M, Vasallo J. p63 and CD10: Reliable markers in discriminating bening sclerosing lesions from tubular carcinoma of the breast? Appl Immunohistochem Mol Morphol 2006;14:71-77.

  17. Barbareschi M, Pecciarini L, Cangi MG, Macri E, et al. p63 a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001;25:1054- 1060.

  18. Werling RW, Hwang H, Yaziji H, Gown AM. Immunohistochemical distinction of invasive from no invasive breast lesions. Am J Surg Pathol 2003;27:82-90.

  19. Wang NP, Wan BC, Skelly M, Frid MG, et al. Antibodies to novel myoepithelium-associated proteins distinguish benign lesions and in situ carcinoma from invasive carcinoma of the breast. Appl Immunohistochem Mol Morphol 1997;5:141- 151.

  20. Kalof AN, Tam D, Beatty B, Cooper K. Immunostaning patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain. J Clin Pathol 2004;57:625-629.

  21. Yaziji H, Sneige N, Gown AM. Comparative sensitivities and specificities of myoepithelial markers in the detection of stromal invasion in breast cancer. Mod Pathol 2000;13:50A.

  22. Hilson JB, Schnitt SJ, Collins LC. Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesionsof the breast. Am J Surg Pathol 2010;34:896-900.

  23. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res Treat 2004;6:149-156.

  24. Nurismah MI, Noriah O, Suryati MY, Sharifah NA. E-cadherin expression correlates with histological type but not tumor grade in invasive breast cancer. Asian Pac J Cancer Prev 2008;9:699-702.

  25. Dabbs DJ, Bhargava R, Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catetin. Am JSurg Pathol 2007;31:427-37.

  26. Fadare O, Tavassoli FA. The phenotypic spectrum of basallike breast cancer: A critical appraisal. Adv Anat Pathol 2007;14:358-373.

  27. Seal MD, Chia SK. What is the difference between triple-negative and basal breast cancers? Cancer J 2010;16:12-16.

  28. Bhargava R, Beriwal S, McManus K, Dabbs DJ. CK5 is more sensitive than CK5/6 in identifying the basal like phenotype of breast carcinoma. Am J Clin Pathol 2008;130:724-730.

  29. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006;19:617-621.

  30. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol 2006;19:1506-1511.

  31. Rakha EA, Reis-Filo JS, Ellis IO. Basal-like breast cancer: A critical review. J Clin Oncol 2008;26:2568-2581.

  32. Nassar H. Carcinomas with micropapillary morphology. Adv Anat Pathol 2004;11:297-303.

  33. Li YS, Kaneko M, Sakamoto DG, Takeshima Y, Inai K. The reversed apical pattern of MUC1 expression is characteristic of invasive micropapillary carcinoma of the breast. Breast Cancer Res Treat 2006;13:58-63.

  34. Luna-More S, Gonzalez B, Acedo C, Rodrigo I, Luna C. Invasive micropapillary carcinoma of the breast: A new special type of invasive mammary carcinoma. Pathol Res Pract1994;190:668-674.

  35. Kuroda N, Sugimoto T, Takahashi T, Morik T, et al. Invasive micropapillary carcinoma of the breast: an immunohistochemical study of neoplasic and stromal cells. Int J Surg Pathol 2005;13:51-55.

  36. Peterson F, Ivan D, Kasakov DV, Michal M, Prieto VG. Pigmented Paget disease: A diagnostic pitfall mimicking melanoma. Am J Dermatopathol 2009;31:223-226.

  37. Perrotto J, Abbott JJ, Ceilley RI, Ahmed I. The role of immunohistochemistry in discriminating primary from secondary extramammary Paget disease. Am J Dermatopathol 2010;32:137-143.

  38. Liegl B, Leibl S, Gogg-Kamerer M, Tessaro B, et al. Mammary and extramammary Paget’s disease: an immunohistochemical study of 83 cases. Histopathology 2007;50:439-447.

  39. Fitzgibbons PL, Murphy DA, Hammond ME, Allred DC, Valenstein PN. Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med 2010;134:930-935.

  40. Hammond ME, Hayes DF, Dowsett M, Allred DC, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;16:2784-2795.

  41. Allerd DC, Bryant JL, Land S, et al. Estrogen receptor status as a predictor of the effectiveness of tamoxifen in CDIS: findings from NSABP Protocol B-24. Mod Pathol 2003;16:21A.

  42. Nassar A, Radhakrshnan A, Cabrero IA, Cotsoins GA, Cohen C. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma. A tissue microarray-based study. Appl Immunohistochem Mol Morphol 2010 (in press).

  43. Bruck P, Vilches N, Ramos E, Barboza O, Ancer J, Flores JP. Expresión del her2neu en el adenocarcinoma ductal de la glándula mamaria: correlación con parámetros histológicos y expresión de receptores estrogénicos en pacientes mexicanas. Ginecol Obstet Mex 2006;74:516-522.

  44. Konency GE, Pauletti G, Pegram M. Quantitative association between HER-2/neu and steroid hormonereceptors in hormone receptor positive primary breast cancer. J Natl Cancer Inst 2003;95:142-153.

  45. Konency GE, Thomssen C, Luck HJ, et al. HER2/neu gen amplification and response to paclitaxel in patients with metastasic breast cancer. J Natl Cancer Inst 2004;96:1141-1151.

  46. Vogel CL, Cobleigh MA, Tripathy D, Guthell JC, et al. Efficacy and safety to trastuzumab as a single agent in first-line treatment of Her2-overexpressing metastasic breast cancer. J Clin Oncol 2002;17:719-726.

  47. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, et al. American Society of Clinical Oncology/College of American Pathologists guidelines recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.

  48. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen Ki-67 and MIB-1. Am J Clin Pathol 1995;104:42-49.

  49. Taneja P, Maglic D, Kai F, Zhu S, et al. Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol 2010;4:15-34.

  50. Olivier M, Langerod A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,749 patients with breast cancer. Clin Cancer Res 2006;12:1157-1167.

  51. Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer. Correlation with luminal subtype A and survival. Clin Cancer Res 2007;13:4415-4421.

  52. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin versus GCDFP-15: an inmmunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007;127:103-113.

  53. Kahn HJ, Marks A. A new monoclonal antibody, D2-40 for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-1257.




2020     |     www.medigraphic.com